By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Amicus Therapeutics, Inc. 

1 Cedar Brook Drive

Cranbury  New Jersey  08512  U.S.A.
Phone: 609-662-2000 Fax: 609-662-2001


Amicus Therapeutics is a global biotechnology company at the forefront of therapies for rare and orphan diseases. We have a unique set of platform technologies and medicines in development for people living with rare and devastating diseases, including the Lysosomal Storage Disorders Fabry disease and Pompe disease, as well as the genetic connective skin disorder Epidermolysis Bullosa (EB).

The needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. Our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers.

Key Statistics

Ownership: Public

Web Site: Amicus
Employees: 100
Symbol: FOLD

Company News
Association Of Medical Device Reprocessors Files Amicus (FOLD) Brief With Supreme Court 3/21/2017 11:17:13 AM
Amicus (FOLD) Plummets on 3-Year Delay to U.S. Fabry Drug FDA Filing Plan 11/29/2016 5:30:54 AM
Amicus (FOLD) Takes Aim at Rare Disease with $90 Million MiaMed Buy 7/7/2016 6:33:11 AM
10 Biotech Stocks Analysts are Upbeat About in May 5/23/2016 8:24:58 AM
Amicus (FOLD) Receives Positive CHMP Opinion For Approval Of Migalastat In Patients With Fabry Disease In European Union 4/1/2016 10:02:02 AM
6 Cheap Biopharma Stocks to Consider 3/25/2016 8:29:54 AM
Three Biotechs Face Near-Term FDA Decisions 3/21/2016 6:36:23 AM
Amicus (FOLD) To Present At The Cowen and Company 36th Annual Health Care Conference 3/3/2016 7:55:52 AM
Three Underperforming Biopharma Companies Worth Looking At 2/15/2016 6:24:02 AM
Amicus (FOLD) Announces Presentations And Posters At 12th Annual Worldsymposium 2016 2/10/2016 8:20:58 AM